Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Wiltrom Co's annualized net income for the quarter that ended in Dec. 2025 was NT$-78.8 Mil. Wiltrom Co's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was NT$582.5 Mil. Therefore, Wiltrom Co's annualized ROE % for the quarter that ended in Dec. 2025 was -13.52%.
The historical rank and industry rank for Wiltrom Co's ROE % or its related term are showing as below:
ROCO:6767'
s ROE % Range Over the Past 10 Years
Min: -13.24 Med: -3.78 Max: 2.65
Current: -3.24
During the past 9 years, Wiltrom Co's highest ROE % was 2.65%. The lowest was -13.24%. And the median was -3.78%.
ROCO:6767's ROE % is ranked worse than 60.08% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.54
vs ROCO:6767: -3.24
Wiltrom Co (ROCO:6767) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Wiltrom Co ROE % Related Terms
Wiltrom Co ROE % Historical Data
* Premium members only.
The historical data trend for Wiltrom Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Wiltrom Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wiltrom Co ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Wiltrom Co's ROE % distribution charts can be found below:
* The bar in red indicates where Wiltrom Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Wiltrom Co (ROCO:6767) has a ROE % of -13.52% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Wiltrom Co and its competitors. According to the industry distribution chart, Wiltrom Co ranks #480 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 60.1%.
Is Wiltrom Co's ROE % too high?
Wiltrom Co's current ROE % is -13.52%. Based on the distribution chart, Wiltrom Co ranks #480 out of 799 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Wiltrom Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wiltrom Co's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Wiltrom Co ranks #480 out of 799 companies for ROE %. This places Wiltrom Co in the lower half of its industry. The industry median ROE % is 2.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.54, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Wiltrom Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wiltrom Co's current ROE % is -13.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wiltrom Co stock overvalued right now?
Based on GuruFocus' analysis, Wiltrom Co (ROCO:6767) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$29.23, compared to a current price of NT$25.45 — trading 12.9% below its estimated fair value. The current ROE % is -13.52%. Wiltrom Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Wiltrom Co (ROCO:6767), the current ROE % is -13.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wiltrom Co (ROCO:6767) Overvalued in 2026?
Based on GuruFocus' analysis, Wiltrom Co stock appears to be undervalued.
The current stock price of NT$25.45 is trading 12.9% below its estimated GF Value™ of NT$29.23.
GuruFocus considers Wiltrom Co to be Modestly Undervalued.
Key valuation signals for ROCO:6767:
ROE %: -13.52%
GF Value™: NT$29.23 vs. price of NT$25.45 (12.9% below fair value)
No single metric tells the full story. See the ROCO:6767 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wiltrom Co Ltd is engaged in research and production of medical devices. Its product portfolio consists of a Spinal fixation system, an Interbody fusion system, a Bone graft substitute, and Vertebral body augmentation system among others.
82GF Score
Get the complete analysis for ROCO:6767
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6767 has been successfully added to your 
